Cardiac Blood Articles & Analysis
6 news found
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences. ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and R&D tax credits from the ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF) patients published in the Journal of Cardiac Failure. ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of results from the Company’s U.S. ...
The wearables provide continuous monitoring of the cardiac systems and blood pressure. Supported by traditional electrocardiogram (ECG) verification, what makes the CardiacSense wearable different is that it uses PPG technology (photoplethysmography) that is free of any movement artifacts (which are the Achilles Heel of traditional PPG) to carry out long-term, ...